MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road
The DOI matches its Crossref record; 201 of the 201 references it cites were found in a registry or an index.
Abstract
The role of the ERK signalling pathway in cancer is thought to be most prominent in tumours in which mutations in the receptor tyrosine kinases RAS, BRAF, CRAF, MEK1 or MEK2 drive growth factor-independent ERK1 and ERK2 activation and thence inappropriate cell proliferation and survival. New drugs that inhibit RAF or MEK1 and MEK2 have recently been approved or are currently undergoing late-stage clinical evaluation. In this Review, we consider the ERK pathway, focusing particularly on the role of MEK1 and MEK2, the 'gatekeepers' of ERK1/2 activity. We discuss their validation as drug targets, the merits of targeting MEK1 and MEK2 versus BRAF and the mechanisms of action of different inhibitors of MEK1 and MEK2. We also consider how some of the systems-level properties (intrapathway regulatory loops and wider signalling network connections) of the ERK pathway present a challenge for the success of MEK1 and MEK2 inhibitors, discuss mechanisms of resistance to these inhibitors, and review their clinical progress.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The limited ef fi cacy observed for MEK inhibitors may involve adaptive feedback mechanisms through the reactivation of MAPK signalling caused by the blockade of ERK signalling [11 -13].”
In the citing paper
“Although RAS/RAF-mutated CRC has been targeted for the development of therapeutic inhibitors, they have been largely ineffective, likely due to complex resistance mechanisms such as intrinsic and adaptive resistance [5–12].”
From An integrative gene expression signature analysis identifies CMS4 KRAS-mutated colorectal cancers sensitive to combined MEK and SRC targeted therapy (2022) · cites this paper as [5]
In the citing paper
“However, MEK inhibitors, used alone, have been largely ineffective, likely due to intrinsic and adaptive resistance mechanisms [5–7].”
From An integrative gene expression signature analysis identifies CMS4 KRAS-mutated colorectal cancers sensitive to combined MEK and SRC targeted therapy (2022) · cites this paper as [5]
In the citing paper
“Previous studies demonstrated that the adaptive reactivation of MAPK signaling in the presence of a MEK inhibitor was mediated by the loss of MAPK-dependent negative feedback loops and the consequent induction of RTKs signaling (26, 53).”
From New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness (2019) · cites this paper as [53]
In the citing paper
“targeting of MEK alone is frequently hampered by adaptive resistance, which is complex and context-dependent, and can involve activation of various RTKs, including ERBB family, AXL, PDGFR-α, or FGFR1 (26, 53, 59–62).”
From New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness (2019) · cites this paper as [53]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Untangling the ErbB signalling network
Yarden, Y., & Sliwkowski, M. X. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052073 · Cited by 6,974
The ground state of embryonic stem cell self-renewal
Ying, Q.-L., Wray, J., Nichols, J., Batlle-Morera, L., Doble, B., Woodgett, J., Cohen, P., & Smith, A. (2008) · Nature · doi:10.1038/nature06968 · Cited by 3,442
Alessi, D. R., Cuenda, A., Cohen, P., Dudley, D. T., & Saltiel, A. R. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.46.27489 · Cited by 3,393
Identification of a Novel Inhibitor of Mitogen-activated Protein Kinase Kinase
Favata, M. F., Horiuchi, K. Y., Manos, E. J., Daulerio, A. J., Stradley, D. A., Feeser, W. S., Van Dyk, D. E., Pitts, W. J., Earl, R. A., Hobbs, F., et al. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.29.18623 · Cited by 3,015
Hauschild, A., Grob, J.-J., Demidov, L. V., Jouary, T., Gutzmer, R., Millward, M., Rutkowski, P., Blank, C. U., Miller, W. H., Kaempgen, E., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60868-x · Cited by 2,989
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
Flaherty, K. T., Infante, J. R., Daud, A., Gonzalez, R., Kefford, R. F., Sosman, J., Hamid, O., Schuchter, L., Cebon, J., Ibrahim, N., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1210093 · Cited by 2,810
Cited by
Items 501–600 of 615
Imoto, H., Rauch, N., Nagasato, A. I., Okada, M., Kölch, W., Rukhlenko, O. S., & Kholodenko, B. Ν. (2026) · npj Systems Biology and Applications · doi:10.1038/s41540-026-00710-6 · Cited by 1
“For instance, Trametinib preferentially binds to non-phosphorylated MEK, whereas Cobimetinib, Selumetinib and Binimetinib do not favor any MEK phosphorylation state 29 .”
Samah, N., Nor, F. M., Razali, W. M. H. W., Mohamad, S. F., Beh, B. C., Hamid, A. A., Ugusman, A., & Aminuddin, A. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27114757 · Cited by 1
“Pharmacological inhibition of upstream MAPK components, such as MEK1/2 inhibitors, has been shown to suppress ERK activation and reduce inflammatory and proliferative signaling in various pathological conditions [48,49].”
A Structural Perspective on Non-covalent Targeting of Conserved Polar Residues in Protein Kinases
Nasief, N. N., Patel, K. B., Ogboo, B. C., & Heppner, D. E. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6c00330 · Cited by 1
Orientation of Preclinical Research in Ovarian Cancer
Baert, T., Garg, A. D., Agostinis, P., Vergote, I. B., & Coosemans, A. (2017) · International Journal of Gynecological Cancer · doi:10.1097/igc.0000000000001053 · Cited by 1
Revolutionizing Cancer Treatment: Unveiling New Frontiers by Targeting the (Un)Usual Suspects
Costa, V., Giovannetti, E., & Lonardo, E. (2023) · Cancers · doi:10.3390/cancers16010132 · Cited by 1
“In this context, the identification of new drugs or drug combinations targeting well-known signaling pathways [5,6], along with the repurposing of approved drugs with undiscovered antitumor activities [7–9], offer refreshed arrays of therapeutic options in oncology.”
Li, Z., Yang, K., Xu, T., Wang, L., Wang, X., Wen, X., Zhang, C., Wang, J., Zheng, X., Wu, T., et al. (2024) · Annals of Hematology · doi:10.1007/s00277-024-06046-7 · Cited by 1
“In AML models driven by RAS-MEK signal activation, the MEK inhibitor trametinib has demonstrated anti-leuke-mic activity both in vitro [8] and in vivo [9], suggesting that patients with r/r RAS-mutated hematologic malignancies might benefit from MEK inhibitor therapy.”
Antiviral Activity of the MEK1/2 Inhibitor Trametinib Against Lymphocytic Choriomeningitis Virus
Mao, W., Wan, Y., Liu, Y., Zhou, M., Jia, X., Hou, Y., & Wang, W. (2025) · Journal of Medical Virology · doi:10.1002/jmv.70267 · Cited by 1
“Given the unique role of MEK1/2 as the exclusive kinase responsible for ERK1/2 phosphorylation in the MAPK signaling pathway [38], an RNAi experiment was conducted to test the consistency of MEK inhibition with trametinib treatment against LCMV infection.”
Visualization of RAS/MAPK Signaling In Situ by the Proximity Ligation Assay (PLA)
Tang, Z., & Dai, C. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-6424-6_14 · Cited by 1
“A number of transcription factors have been identified as ERKs’ targets including ETS-1, c-JUN and c-MYC [8].”
BackgroundArba, M., Ruslin, R., Nursan, N., Maulidiyah, M., & Tjahjono, D. H. (2018) · Jurnal Kimia VALENSI · doi:10.15408/jkv.v4i1.7454 · Cited by 5
Molecular Pathology and Genomics of Melanoma
Griewank, K., Murali, R., & Wiesner, T. (2020) · Springer eBooks · doi:10.1007/978-3-030-05070-2_41 · Cited by 3
The Activation of MEK1 by Enhanced Homodimerization Drives TumorigenesisPreprint
Yuan, J., Ng, W. H., Tian, Z., Yap, J., Baccarini, M., Chen, Z., & Hu, J. (2017) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/229849 · Cited by 1
Urisman, A., Yuan, T. L., Trinidad, M. I., Morris, J. H., Afghani, S., Osés-Prieto, J. A., Ritchie, C. D., Zahari, M. S., Benes, C. H., Burlingame, A. L., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/695460 · Cited by 1
“However, so far, these compounds have not produced clinically significant effects in KRAS-mutant tumors [8].”
BackgroundHafner, M. A., Mills, C. E., Subramanian, K., Chen, C., Chung, M., Boswell, S. A., Everley, R. A., Liu, C., Walmsley, C. S., Juric, D., et al. (2018) · SSRN Electronic Journal · doi:10.2139/ssrn.3285804 · Cited by 1
McBrearty, N. (2019) · TUScholarShare (Temple University) · Cited by 1
The Dual Power of the State-Party and Its Grounds
Horváth, Á., & Szakolczai, Á. (1990) · Cited by 1
Selective inhibitors of JAK1 targeting a subtype-restricted allosteric cysteinePreprint
Kavanagh, M. E., Horning, B. D., Khattri, R., Roy, N., Lu, J. P., Whitby, L. R., Brannon, J. C., Parker, A., Chick, J. M., Eissler, C. L., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.01.31.478302 · Cited by 1
Hexokinase 1b is a novel target for Non–small-cell lung cancerPreprint
Yozgat, Y., Karakoç, E., Şahin, Ö., Çimen, Ş., Rabeh, W. M., Aydın, M. Ş., Mardinoğlu, A., Gürsel, İ., Çakır, A., Şensoy, Ö., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.06.27.497447 · Cited by 2
de Looff, M., Heng, W. S., de Jong, S., & Kruyt, F. A. E. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.08.10.503463 · Cited by 1
“MEK1 and MEK2 are part of the RAS mediated RAF-MEK1/2-ERK proliferation and survival pathway that is often hyperactivated in lung cancers (35,36).”
BackgroundChalcones: An insight into their anticancer potential and action mechanismPreprint
Darandale, S., Kadam, K. R., More, V. K., Hase, D., Hase, V., & Gurav, S. S. (2023) · SSRN Electronic Journal · doi:10.2139/ssrn.4573587 · Cited by 2
Revazian, A., Nesterenko, A. M., Ezeriņa, D., Luo, T., Vertommen, D., Gibhardt, C. S., Bogeski, I., Messens, J., & Belousov, V. V. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.10.17.618419 · Cited by 1
SHP2 binds directly to SOS1 to enable RAS activationPreprint
Araki, T., Agrawal, Y., Katti, S. S., Nguyen, H. L. D., Yeggoni, D. P., Geer, M. J., Wei, W., Woutersen, D. T. J., Bijlsma, T., Lian, C. G., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.06.12.731952 · Cited by 3
A chemical genetic approach to identify new treatments for melanoma
Hanson, K. (2015) · UEA Digital Repository (University of East Anglia)
Insulin Signaling Linking Metabolism and Malignancy
Kessler, S. M., & Kiemer, A. K. (2017) · Springer eBooks · doi:10.1007/978-3-319-53659-0_4
The role of fibroblasts in cancer progression, therapy resistance and field cancerization
Chan, J. S. K. (2017) · DR-NTU (Nanyang Technological University) · doi:10.32657/10356/72335
Ruder, D. (2016) · Digital Commons-TMC (Texas Medical Center)
Combinations of Genomically and Immune-Targeted Therapies in Early-Phase Clinical Trials
Patel, M. R., Patel, S. P., & Kurzrock, R. (2017) · Current cancer research · doi:10.1007/978-3-319-63757-0_9
The Dawning of Translational Breast Cancer: From Bench to Bedside
Chen, X., Fan, S., & Song, E. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-981-10-6020-5_1
Anti-Proliferative Effects of Garcinia Fruits in Breast Cancer Cells
Senthilkumar, H. A. (2018)
Signaling Pathways as Therapeutic Targets in Pediatric B-cell Precursor Acute Lymphoblastic Leukemia
Jerchel, I. S. (2018) · RePub (Erasmus University Rotterdam)
Principles of Targeted Therapy
Bollag, G. E., & Flaherty, K. T. (2018) · Springer eBooks · doi:10.1007/978-1-4614-7322-0_35-1
Translational Research and Genomics Driven Trials in Thyroid Cancer
Cabanillas, M. E., Schweppe, R. E., Dadu, R., Cote, G. J., Beadnell, T. C., & Hofmann, M.-C. C. (2018) · Springer eBooks · doi:10.1007/978-3-319-91725-2_24
Investigations into how best to target FGFR2 mutant endometrial cancer
Geng, X. (2017) · Queensland University of Technology · doi:10.5204/thesis.eprints.123437
Blocking KRAS Signaling for the Treatment of Lung Cancer: Mission Possible?
Horio, Y. (2018) · Haigan · doi:10.2482/haigan.58.953
Molecular Pathways in Melanomagenesis
Pasini, L. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-811785-9.00044-2
Emerging Novel Therapies in Overcoming Resistance to Targeted Therapy
Pinho, A. V., Lee, J., & Rizos, H. (2019) · Resistance to targeted anti-cancer therapeutics · doi:10.1007/978-3-030-21477-7_8
Combinational delivery therapies of nucleic acids for cancer treatment
Madkour, L. H. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-819777-6.00015-9
Wilhelm, T., Toledo, M. A. S., Simons, I., Stuth, C., Mohta, V., Mülfarth, R. I., Nitsche, M., Maschke-Neuss, K., Schmitz, S., Kaiser, A., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.08.31.266734
“A reduction of the cellular MEK inhibitor/MEK molecule ratio, provoked by cellular resistance mechanisms or missing patient compliance, can then cause vehement re-activation of the MEK/ERK pathway (Caunt et al. 2015).”
BackgroundMethodWong, K. U., Shi, S. L., Wang, H., Xing, F., Quan, Y., Zhao, M., Zhang, L., Wong, K. H.-M., Wong, A. H., & Deng, C. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/499723
“Erk signaling pathway is well-known for promoting cell proliferation [20] and motility [21], both of which attributes to enhance tumorigenesis and metastasis.”
BackgroundBucko, P. J. (2020) · ResearchWorks at the University of Washington (University of Washington)
Dual MAPK and HDAC inhibition rewires the apoptotic rheostat to trigger colorectal cancer cell deathPreprint
Jenkins, L. J., Luk, I. Y., Palmieri, M., Fairlie, W. D., Lee, E. F., Schoffer, K. L., Tan, T., Ng, I., Vukelic, N., Tse, J. W. T., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.02.15.431252
“The latter approach may provide greater tumour-specific targeting and a better therapeutic window compared to MEK inhibition where on-target toxicities in normal cells may reduce clinical activity [34].”
BackgroundMechanism of kinetin-induced death of Vicia faba ssp. minor cortex cellsPreprint
Kaźmierczak, A., Kunikowska, A., Doniak, M., & Kornaś, A. (2021) · Research Square · doi:10.21203/rs.3.rs-226515/v1
US FDA‐Approved Small‐Molecule Kinase Inhibitors for Cancer Therapy
Yu, M., Tadesse, S., & Wang, S. (2021) · Wiley eBooks · doi:10.1002/0471266949.bmc214.pub2
Harrison, E. M., Khan, S., Balasubramaniyan, V., & de Groot, J. F. (2021)
Prospects for Targeted Kinase Inhibition in Cancer: Neurofibromatosis Type 1-Related Neoplasia
Rhodes, S. D., & Angus, S. P. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00174-2 · Cited by 1
Especial diseño 2007: 5 claves para el diseño español
Faerna, J. M., & Astigarraga, M. P. (2007) · Diseño interior
Untersuchung synthetischer Letalität in Vincristin-resistenten Neuroblastomzellen
Zeitz, K. (2021) · Publication Server of Goethe University Frankfurt am Main (Goethe University Frankfurt) · doi:10.21248/gups.64012
Brady, D. C. (2018) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.732763476.793553192
El‐Deiry, W. S., & Borerro, L. H. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.735662150.793560370
Starý, J., & Vakrmanová, B. (2017) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.731684918.793538374
Principles of Targeted Therapy
Bollag, G. E., & Flaherty, K. T. (2019) · Springer eBooks · doi:10.1007/978-1-4614-7147-9_35
Mechanisms of non-apoptotic TRAIL signalling in NSCLC
de Looff, M. (2022) · University of Groningen research database (University of Groningen / Centre for Information Technology) · doi:10.33612/diss.222500491
Cellular response to compartmentalized redox alterations
Revazian, A. (2022) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-9408
Gu, W., & Zhang, C. (2022) · Research Square · doi:10.21203/rs.3.rs-2115229/v1
Identification of NRAS Downstream Genes with CRISPR Activation Screening
Tatsumi, A., Hirakochi, H., Inoue, S., Tanaka, Y., Furuno, H., Ikeda, M., Ishibashi, S., Taguchi, T., Yamamoto, K., Onishi, I., et al. (2022) · Biology · doi:10.3390/biology11111551
“The RAS/MEK/ERK pathway is a general cancer cell growth signal [15], but treatment with MEK inhibitors downstream of the pathway has been reported to have limited efficacy in some tumors [8].”
BackgroundSchulz, W. A. (2023) · Springer eBooks · doi:10.1007/978-3-031-16286-2_6
Studies of Erk1/2 with Respect to Tumor Aggressiveness in B16f10 Murine Melanoma Cells
Moulik, S., Karmakar, S., Basu, A., Mukherjee, S., Neeraja, R. , & -, A. C. (2023) · International Journal For Multidisciplinary Research · doi:10.36948/ijfmr.2023.v05i01.1733
Data from mTOR Activation Initiates Renal Cell Carcinoma Development by Coordinating ERK and p38MAPK
Wu, H., He, D., Biswas, S., Shafiquzzaman, M., Zhou, X., Charron, J., Wang, Y., Nayak, B. K., Habib, S. L., Liu, H., et al. (2023) · doi:10.1158/0008-5472.c.6513277.v1
Schmidt, S., Linge, A., Zwanenburg, A., Leger, S., Lohaus, F., Krenn, C., Appold, S., Gudziol, V., Nowak, A., von Neubeck, C., et al. (2023) · doi:10.1158/1078-0432.22461530.v1
Dennison, L., Ruggieri, A. N., Mohan, A. A., Leatherman, J., Cruz, K. A., Woolman, S., Azad, N. S., Lesinski, G. B., Jaffee, E. M., & Yarchoan, M. M. (2023) · doi:10.1158/2326-6066.c.6550348
Dennison, L., Ruggieri, A. N., Mohan, A. A., Leatherman, J., Cruz, K. A., Woolman, S., Azad, N. S., Lesinski, G. B., Jaffee, E. M., & Yarchoan, M. M. (2023) · doi:10.1158/2326-6066.c.6550348.v1
Pancreatic Cancer: A Review on Pathophysiology, Naturopathy, Clinical Treatment and Outcomes
Chakraborty, R., Dutta, A., Baruah, B. J., Kumari, R., Sarma, P., Sharma, A., Goswami, K., Myakala, H., & Verma, A. K. (2023) · Current Cancer Therapy Reviews · doi:10.2174/1573394719666230830125213
Vuaroqueaux, V., Musch, A., Peille, A.-L., Kelter, G., Weichert, L., Metz, T., Hendriks, H. R., & Fiebig, H. (2023) · doi:10.1158/2767-9764.c.6897312
Horinaka, M., Yoshimura, A., Yaoi, T., Ono, H., Itoh, K., Yamada, T., Takayama, K., & Sakai, T. (2023) · Research Square · doi:10.21203/rs.3.rs-3558262/v1
Drug Resistance Mechanism of Tri-ple-Negative Breast Cancer and Research Progress with DLG5
王, 旭. (2023) · Advances in Clinical Medicine · doi:10.12677/acm.2023.13112537
Schulz, W. A. (2024) · Springer eBooks · doi:10.1007/978-3-031-42806-7_6
Durai, P., Lee, S. J., Lee, J. W., Pan, C., & Park, K. (2023) · Figshare · doi:10.6084/m9.figshare.24187879
Nivetha, T., Monisha, M., & Paramasivam, G. (2024) · AIP conference proceedings · doi:10.1063/5.0197440
Marx, M. A., Hallin, J. F., Christensen, J. G., & Fell, B. (2024) · Medicinal chemistry reviews · doi:10.1021/mc-2024-vol59.ch17
Ikeda, J., Shiba, N., Kato, S., Kunimoto, H., Saito, Y., Sagisaka, M., Ito, M., Goto, H., Okuno, Y., Nakamura, W., et al. (2025) · International Journal of Hematology · doi:10.1007/s12185-025-03929-x · Cited by 1
“However, monotherapy with MEK inhibitors has limited clinical efficacy in AML patients with the RAS mutation due to the presence of complex feedback loops and bypasses [22].”
The identification of functional regions of MEK1 using CRISPR tiling screens
Zhang, Z., Abreu, B., Brothwood, J. L., Alexander, J. J., Sims, M., Lyons, J. F., Munck, J. M., & Hindley, C. J. (2025) · Communications Biology · doi:10.1038/s42003-025-07966-4 · Cited by 1
“Mitogen-activated protein kinase kinase 1 (MEK1), coded by MAP2K1 gene, is a key component of the mitogen-activated protein kinase (MAPK) pathway 17 .”
Gao, L., Wang, S., Hu, X., Wang, L., Xi, Y., Bu, P., Zhao, G., Zhao, L., Yang, Y., & Zhao, H. (2025) · Translational Cancer Research · doi:10.21037/tcr-2025-666
“MEK1/2 signaling hyperactivation occurs frequently in malignant tumors, and thus can be used as a target for anti-cancer therapy (9,10).”
Tan, F., Yin, W., Wang, Z., You, L., Li, Y., & Xia, H. (2025) · Research Square · doi:10.21203/rs.3.rs-6350378/v1
Vadivel, P., Thirumurugan, C., Lalitha, A., & Thirumalaisamy, R. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5269245
Integrative transcriptomic analysis of Korean high-grade serous ovarian cancer
Kim, H., Kim, Y.-W., Park, J., Shin, D.-M., Kim, J. H., Gunathilake, M. N., Kwon, S. Y., Shin, J., Yoo, C. W., Park, S., et al. (2025) · PLoS Genetics · doi:10.1371/journal.pgen.1011660
“MAP2K1 encodes a mitogen-activated protein kinase (MAPK), which exhibits activating mutations implicated in several cancers including ovarian, melanoma, and lung cancers, and its inhibition has demonstrated efficacy in restraining tumor growth in these contexts [30].”
Zhao, Y., Zhu, X., Zhang, J., Wang, W., Cui, C., Tan, X., Liu, X., Xu, X., Li, Z., & Yang, J. (2025) · Biology · doi:10.3390/biology14101338
“The MEK1 protein encoded by MAP2K1 has a significant function in the Ras/MAPK pathway that controls many cellular and developmental processes [42,43].”
Lv, L., Sun, X., Zhang, H., Wang, G., Zhang, C., Liu, H., & Zhu, L. (2025) · Molecular Medicine Reports · doi:10.3892/mmr.2025.13724
“…MEK, RAF and erK are activated sequentially in a phosphorylation‑dependent cascade, with erK1/2 ultimately phosphorylating downstream effectors which regulate numerous physiological processes, including proliferation, transcription, survival, cell adhesion, growth and differentiation (35,37,38).”
An integrated platform for high-throughput phenospace learning of 3D multilineage organoid systemsPreprint
Okuda, R., Harmel, C., Xu, Q., Mary, H., Schulz, P., Steinacher, L., D’Arcangelo, E., Gjeta, B., Signer, M., Cubela, I., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.11.27.690952
Ren, L.-X., Qi, J.-C., Zhao, A.-N., Shi, B., Zhang, H., Wang, D., & Yang, Z. (2021) · Figshare · doi:10.6084/m9.figshare.14870434
Additional file 1 of The safety and efficacy of binimetinib for lung cancer: a systematic review
Zahmatyar, M., Kharaz, L., Abiri Jahromi, N., Jahanian, A., Shokri, P., & Nejadghaderi, S. A. (2024) · Figshare · doi:10.6084/m9.figshare.26461750
Additional file 2 of The safety and efficacy of binimetinib for lung cancer: a systematic review
Zahmatyar, M., Kharaz, L., Abiri Jahromi, N., Jahanian, A., Shokri, P., & Nejadghaderi, S. A. (2024) · Figshare · doi:10.6084/m9.figshare.26461917
Additional file 2 of PML-II regulates ERK and AKT signal activation and IFNα-induced cell death
Meng, X., Chen, Y., Macip, S., & Leppard, K. N. (2021) · Figshare · doi:10.6084/m9.figshare.14903798
Hu, X., Li, W., Zeng, K., Xu, Z., Li, C., Kang, Z., Li, S., Huang, X., Han, P., Lin, H., et al. (2023) · Figshare · doi:10.6084/m9.figshare.23621322
Ren, L.-X., Qi, J.-C., Zhao, A.-N., Shi, B., Zhang, H., Wang, D., & Yang, Z. (2021) · Figshare · doi:10.6084/m9.figshare.14870431
Durai, P., Lee, S. J., Lee, J. W., Pan, C.-H., & Park, K. (2023) · Figshare · doi:10.6084/m9.figshare.24187876
Wang, Y., Xiao, P., Fan, L., Pan, Y., Ma, H., Wang, R., Xu, C., & Zhang, L. (2026) · Analytical Chemistry · doi:10.1021/acs.analchem.5c05557
“13 These kinases share extensive structural homology, including conserved domains in various functional aspects.”
Ran, S., Wang, S., Li, R., Lai, L., Yu, J., Zhang, X., Li, Y., Ye, W., Zong, J., Li, X., et al. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-026-08023-2 · Cited by 1
“Some previous studies have revealed favorable immunomodulatory effects of MEK1/2 inhibitor on the tumor microenvironment via various mechanisms [46].”
Zhao, T., Xu, L., Huang, W., Wang, C., Wang, H., Du, M., Yao, C., & Xu, Y. (2026) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2026.178810
Vadivel, P., Thirumurugan, C., Thirumalaisamy, R., & Lalitha, A. (2026) · In Silico Pharmacology · doi:10.1007/s40203-026-00599-3
Lu, Y., Liu, J. B., Li, Y., Xiang, L., Song, G.-B., Peng, T., Wang, Z., Yang, X., Ying, H., & Cheng, X.-X. (2026) · Cell Death and Disease · doi:10.1038/s41419-026-08812-z
“Activating mutations frequently arise in core components such as RTKs, RAS, BRAF, CRAF, MEK1, and MEK2, converting these proteins into oncogenic drivers that sustain aberrant ERK activation and render tumor cells highly dependent on this pathway [19].”
Yang, C., Liu, M., Hou, X., Zhang, W., Tian, Z., Zhang, J., & Zhu, Y. U. N. L. O. N. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-026-08260-5
“For instance, studies have demonstrated that copper ions can directly bind to MEK1 and MEK2 kinases, positively regulating the entire MAPK/ERK signalling cascade by promoting their interaction with RAF kinases and their subsequent phosphorylation [55, 56].”
MEK inhibitor cobimetinib increases calreticulin and induces immune modulation in TNBC
Tseng, L., Lau, K.-Y., Chen, J.-L., Chu, P.-Y., Huang, C., Wang, W., Chang, Y.-Y., Lai, J., Huang, C., Dai, M., et al. (2026) · Journal of Molecular Medicine · doi:10.1007/s00109-026-02684-8 · Cited by 1
“This results in the accumulation of phosphorylated MEK1/2, which differs from the effect of trametinib [ 38].”
Hamza, H., Ghosh, M., Rammensee, H., & Planz, O. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1790267
Song, C., Ma, L., Xu, Y., Xu, Y., Zhang, Q., Liu, Y., Song, C., & Lin, Y. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2520561123
MEK Inhibitors and Toll-like Receptor Signaling: Implications for Infection and Inflammation
Planz, O. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27135666
“As a result, MEK inhibitors represent one of the best-characterized classes of targeted kinase inhibitors in clinical use [25,52–54].”
Heumann, T. R., Lu, J., Wang, H., Phelps, M. A., Zhu, Q., Anders, R. A., Mitchell, S., Leatherman, J. M., Abbott, N., Kim, K., et al. (2026) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-4893 · Cited by 2
Kolitz, S. E., Travesa, A., Axel, A. E., Funt, J. M., Nord, M. S., Yamamura, A., Fowler, K. D., Nair, P., Zeskind, B. J., Hall, B. M., et al. (2026) · Cancer Research · doi:10.1158/0008-5472.can-25-4907
“Chronic MEK inhibition leads to narrow therapeutic windows, high class-effect SAEs, and acquired resistance in tumor cells (15).”
Influential
Metadata
- Authors
- Caunt, C. J., Sale, M. J., Smith, P. D., & Cook, S. J.
- Affiliations
- University of Bath (GB)
- Babraham Institute (GB)
- AstraZeneca (United Kingdom) (GB)
- Corresponding author
- Smith, Paul D.
- Cook, Simon J.
- Venue
- Nature Reviews Cancer
- Published
- 2015-09-24
- Volume
- 15
- Issue
- 10
- Pages
- 577-592
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W1848470479
- Cited by
- 606
- References
- 201
- Citations by year
- 2026: 27 · 2025: 44 · 2024: 61 · 2023: 48 · 2022: 69 · 2021: 73 · 2020: 47 · 2019: 62 · 2018: 70 · 2017: 66 · 2016: 33 · 2015: 4
- FWCI
- 5.65
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Cancer Research UK (14867)
- Biotechnology and Biological Sciences Research Council (BBS/E/B/0000C199, BBS/E/B/000C0417, BBS/E/B/0000H248, BBS/E/B/000C0419, BBS/E/B/0000H151)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Keywords
- MEK1 inhibitor, ERK signaling, Raf/MEK/ERK pathway, BRAF mutation, RAS mutations, Raf-1, drug resistance mechanisms, carcinogenesis, cancer therapy
- MeSH terms
- Humans, Neoplasms, Signal Transduction, MAP Kinase Signaling System, Protein Kinase Inhibitors, MAP Kinase Kinase 1, MAP Kinase Kinase 2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.